As obesity and metabolic diseases balloon worldwide, Ethicon Inc./Johnson & Johnson is hoping to grow its products’ market share and to expand access to bariatric surgery to patients in countries where access is limited due to a variety of factors, by funding clinical research. In a market that has been flat in recent years, Ethicon hopes that by funding these investigations, it will convince payors in a handful of countries that the return on investment for the cost of bariatric surgery outweighs the cost of treating obesity-related disease.
On June 30, Ethicon announced a $3.2 million investment in clinical research to “better understand how earlier surgical intervention may improve conditions such as obesity and type 2 diabetes,” the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?